Stuttering Treatment Research 1970–2005: II. Systematic Review Incorporating Trial Quality Assessment of Pharmacological Approaches
Publication: American Journal of Speech-Language Pathology
Volume 15, Number 4
Pages 342-352
Abstract
Purpose
To complete a systematic review, incorporating trial quality assessment, of published research about pharmacological treatments for stuttering. Goals included the identification of treatment recommendations and research needs based on the available high-quality evidence.
Method
Multiple readers reviewed 31 articles published between 1970 and 2005, using a written data extraction instrument developed as a synthesis of existing standards and recommendations. Articles were then assessed using 5 methodological criteria and 4 outcomes criteria, also developed from previously published recommendations.
Results
None of the 31 articles met more than 3 of the 5 methodological criteria (M = 1.74). Four articles provided data to support a claim of short-term improvement in social, emotional, or cognitive variables. One article provided data to show that stuttering frequency was reduced to less than 5%, and 4 additional articles provided data to show that stuttering may have been reduced by at least half. Among the articles that met the trial quality inclusion criterion for the second stage of this review, none provided uncomplicated positive reports.
Conclusions
None of the pharmacological agents tested for stuttering have been shown in methodologically sound reports to improve stuttering frequency to below 5%, to reduce stuttering by at least half, or to improve relevant social, emotional, or cognitive variables. These findings raise questions about the logic supporting the continued use of current pharmacological agents for stuttering.
Get full access to this article
View all available purchase options and get full access to this article.
References
Abwender, D. A., Trinidad, K. S., Jones, K. R., Como, P. G., Hymes, E., & Kurlan, R. (1998). Features resembling Tourette’s syndrome in developmental stutterers. Brain and Language, 62, 455–464.
Althaus, M., Vink, H., Minderaa, R., Goorhuis-Brouwer, S., & Oosterhoff, A. (1995). Lack of effect of clonidine on stuttering in children. The American Journal of Psychiatry, 152, 1087–1089.
American Speech-Language-Hearing Association. (2005). Evidence-based practice in communication disorders [Position statement]. Available from www.asha.org/reference
Andrews, G., & Dosza, M. (1977). Haloperidol and the treatment of stuttering. Journal of Fluency Disorders, 2, 217–224.
Bloodstein, O. (1981). A handbook on stuttering (3rd ed.). Chicago: The National Easter Seal Society.
Bloodstein, O. (1995). A handbook on stuttering (5th ed.). San Diego, CA: Singular.
Bothe, A. K., Davidow, J. H., Bramlett, R. E., & Ingham, R. J. (2006). Stuttering treatment research 1970–2005: I. Systematic review incorporating trial quality assessment of behavioral, cognitive, and related approaches. American Journal of Speech-Language Pathology, 15, 321–341.
Brady, J. (1991). The pharmacology of stuttering: A critical review. American Journal of Psychiatry, 148, 1309–1316.
Brady, J., & Ali, Z. (2000). Alprazolam, citalopram, and clomipramine for stuttering. Journal of Clinical Psychopharmacology, 20, 287.
Brady, J., Price, T., McAllister, T., & Dietrich, K. (1989). A trial of verapamil in the treatment of stuttering in adults. Biological Psychiatry, 25, 626–630.
Brady, J. P, & Rynn, M. (1994). Stuttering: Current pharmacological options. CNS Drugs, 1, 263–268.
Brin, M., Stewart, C., Blitzer, A., & Diamond, B. (1994). Laryngeal botulinum toxin injection for disabling stuttering in adults. Neurology, 44, 2262–2266.
Brumfitt, S. M., & Peake, M. D. (1988). A double-blind study of verapamil in the treatment of stuttering. British Journal of Disorders of Communication, 23, 35–40.
Chambless, D. L., & Hollon, S. D. (1998). Defining empirically supported therapies. Journal of Consulting and Clinical Psychology, 66, 7–18.
Cochrane, A. L. (1972). Effectiveness and efficiency. Random reflections on health services. London: Nuffield Provincial Hospitals Trust.
Cocores, J., Dackis, C., Davies, R., & Gold, M. (1986). Propranolol and stuttering. [Letter to the editor]. The American Journal of Psychiatry, 143, 1071–1072.
Comings, D. E., & Comings, B. G. (1994). TS, learning, and speech problems. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 429–430.
Conture, E. G., & Guitar, B. E. (1993). Evaluating efficacy of treatment of stuttering: School-age children. Journal of Fluency Disorders, 18, 253–287.
Cook, D. J., Guyatt, G. H., Laupacis, A., Sackett, D. L., & Goldberg, R. J. (1995). Clinical recommendations using levels of evidence for antithrombotic agents. Chest, 108(4, Suppl.), 227S–230S.
Costa, A. D., & Kroll, R. M. (1995). Sertraline in stuttering. Journal of Clinical Psychopharmacology, 15, 443–444.
Costa, D. (1992). Antidepressants and the treatment of stuttering [Letter to the editor]. The American Journal of Psychiatry, 149, 1281.
Curlee, R. F. (1993). Evaluating treatment efficacy for adults: Assessment of stuttering disability. Journal of Fluency Disorders, 18, 319–331.
Davidow, J. H., Bothe, A. K., & Bramlett, R. E. (2006). The Stuttering Treatment Research Evaluation and Assessment Tool (STREAT): Evaluating treatment research as part of evidence-based practice. American Journal of Speech-Language Pathology, 15, 126–141.
Davidow, J. H., Bramlett, R. E., & Bothe, A. K. (2005). Pharmacological Stuttering Treatment Research Evaluation and Assessment Tool (P-STREAT) [Data extraction instrument]. Athens: The University of Georgia.
Erickson, R. L. (1969). Assessing communication attitudes among stutterers. Journal of Speech and Hearing Research, 12, 711–724.
Gardner, D. M., Baldessarini, R. J., & Waraich, P. (2005). Modern antipsychotic drugs: A critical overview. Canadian Medical Association Journal, 172, 1703–1711.
Goberman, A. M., & Blomgren, M. (2003). Parkinsonian speech disfluencies: Effects of L-dopa-related fluctuations. Journal of Fluency Disorders, 28, 55–70.
Goldstein, J. A. (1987). Carbamazepine treatment for stuttering [Letter to the editor]. Journal of Clinical Psychiatry, 48, 39.
Gordon, C., Cotelingam, G., Stager, S., Ludlow, C., Hamburger, S., & Rapoport, J. (1995). A double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. Journal of Clinical Psychiatry, 56, 238–242.
Harvey, J., Culatta, R., Halikas, J., Sorenson, J., Luxenberg, M., & Pearson, V. (1992). The effects of carbamazepine on stuttering. Journal of Nervous and Mental Disease, 180, 451–457.
Ingham, J. C., & Riley, G. (1998). Guidelines for documentation of treatment efficacy for young children who stutter. Journal of Speech, Language, and Hearing Research, 41, 753–770.
Ingham, R. J. (1984). Stuttering and behavior therapy: Current status and experimental foundations. San Diego, CA: College-Hill Press.
Ingham, R. J. (1998). On learning from speech-motor control research on stuttering. In Cordes, A. K., & Ingham, R. J. (Eds.), Treatment efficacy for stuttering: A search for empirical bases (pp. 67–101). San Diego, CA: Singular.
Ingham, R. J., & Cordes, A. (1997). Self-measurement and evaluating stuttering treatment efficacy. In Curlee, R. F., & Siegal, G. M. (Eds.), Nature and treatment of stuttering: New directions (2nd ed., pp. 413–437). Boston: Allyn & Bacon.
Ingham, R. J., & Costello, J. M. (1984). Stuttering treatment outcome evaluation. In Costello, J. M. (Ed.), Speech disorders in adults: Recent advances (pp. 189–223). San Diego, CA: College-Hill Press.
Klasco, R. K. (Ed.), 2004). USP DI®: Drug information for the healthcare professional. Greenwood Village, CO: Thomson Micromedex.
Kymissis, P., & Martin, E. (1990). Antistuttering medication? [Letter to the editor]. Journal of American Academic Child and Adolescent Psychiatry, 29, 840.
Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2004). Drug information handbook (12th ed.). Hudson, OH: Lexi-Comp/APhA.
Lavid, N., Franklin, D., & Maguire, G. (1999). Management of child and adolescent stuttering with olanzapine: Three case reports. Annals of Clinical Psychiatry, 11, 233–236.
Maguire, G. A., Gottschalk, L. A., Riley, G. D., Franklin, D. L., Bechtel, R. J., & Ashurst, J. (1999). Stuttering: Neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity. Comprehensive Psychiatry, 40, 308–314.
Maguire, G., Riley, G., Franklin, D., & Gottschalk, L. (2000). Risperidone for the treatment of stuttering. Journal of Clinical Psychopharmacology, 20, 479–482.
Maguire, G. A., Yu, B. P., Franklin, D. L., & Riley, G. D. (2004). Alleviating stuttering with pharmacological interventions. Expert Opinion on Pharmacotherapy, 5, 1565–1571.
Moscicki, E. K. (1993). Fundamental methodological considerations in controlled clinical trials. Journal of Fluency Disorders, 18, 183–196.
Oberlander, E., Schneier, F., & Liebowitz, M. (1993). Treatment of stuttering with phenelzine [Letter to the editor]. American Journal of Psychiatry, 150, 355.
Oxford Centre for Evidence-Based Medicine. (2006). Levels of evidence and grades of recommendation. Retrieved March 3, 2006, from www.cebm.net/levels_of_evidence.asp
Prins, D., Mandelkorn, T., & Cerf, F. A. (1980). Principal and differential effects of haloperidol and placebo treatments upon speech disfluencies in stutterers. Journal of Speech and Hearing Research, 23, 614–629.
Rantala, S. L., & Petri-Larmi, M. (1976). Haloperidol (serenase) in the treatment of stuttering. Folia Phoniatrica, 28, 354–361.
Riley, G. D. (1994). Stuttering Severity Instrument for Children and Adults, Third Edition. Austin, TX: Pro-Ed.
Rosenberger, P. B., Wheelden, J. A., & Kalotkin, M. (1976). The effect of haloperidol on stuttering. American Journal of Psychiatry, 133, 331–334.
Rothenberger, A., Johannsen, H., Schulze, H., Amorosa, H., & Rommel, D. (1994). Use of tiapride on stuttering in children and adolescents. Perceptual and Motor Skills, 79, 1163–1170.
Rustin, L., Kuhr, A., Cook, P., & James, I. (1981). Controlled trial of speech therapy versus oxprenolol for stammering. British Medical Journal, 283, 517–519.
Sackett, D. L., Straus, S. E., Richardson, W. S., Rosenberg, W., & Haynes, R. B. (2000). Evidence-based medicine: How to practice and teach EBM (2nd ed.). New York: Churchill Livingstone.
Sallee, F. R., Nesbitt, L., Jackson, C., Sine, L., & Sethuraman, G. (1997). Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. American Journal of Psychiatry, 154, 1057–1062.
Sandor, P. (2003). Pharmacological management of tics in patients with TS. Journal of Psychosomatic Research, 55, 41–48.
Schiavetti, N., & Metz, D. E. (2002). Evaluating research in communicative disorders (4th ed.). Boston: Allyn & Bacon.
Shumak, I. C. (1955). A speech situation rating sheet for stutterers. In Johnson, W., & Leutennegger, R. R. (Eds.), Stuttering in children and adults: Thirty years of research at the University of Iowa (pp. 341–347). Minneapolis: University of Minnesota Press.
Silverstone, T. (1970). The use of drugs in behavior therapy. Behavior Therapy, 1, 487–497.
Smith, A., Denny, M., Shaffer, L. A., Kelly, E. M., & Hirano, M. (1996). Activity of intrinsic laryngeal muscles in fluent and disfluent speech. Journal of Speech and Hearing Research, 39, 329–348.
Stager, S. V., Calis, K., Grothe, D., Bloch, M., Berensen, N. M., Smith, P. J., & Braun, A. (2005). Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter. Journal of Fluency Disorders, 30, 319–335.
Stager, S., Ludlow, C., Gordon, C., Cotelingam, M., & Rapoport, J. (1995). Fluency changes in persons who stutter following a double blind trial of clomipramine and desipramine. Journal of Speech and Hearing Research, 38, 516–525.
Sweetman, S. C. (Ed.), 2004). Martindale: The complete drug reference. Greenwood Village, CO: Thomson Micromedex.
Swift, W., Swift, E., & Arellano, M. (1975). Haloperidol as a treatment for adult stuttering. Comprehensive Psychiatry, 16, 61–67.
Vink, H., Althaus, M., Goorhuis-Brouwer, S., & Minderaa, R. (1992). Clonidine and stuttering [Letter to the editor]. American Journal of Psychiatry, 149, 717.
Wells, P. G., & Malcolm, M. T. (1971). Controlled trial of the treatment of 36 stutterers. British Journal of Psychiatry, 119, 603–604.
Wickersham, R. M., & Novak, K. K. (Eds.), 2005). Drug facts and comparisons. St. Louis, MO: Wolters Kluwer Health.
Woolf, G. (1967). The assessment of stuttering as struggle, avoidance, and expectancy. British Journal of Disorders of Communication, 2, 158–171.
Wu, J. C., Maguire, G., Riley, G., Lee, A., Keator, D., & Tang, C. (1997). Increased dopamine activity associated with stuttering. Neuroreport, 8, 767–770.
Information & Authors
Information
Published In
Copyright
Copyright © 2006 American Speech-Language-Hearing Association.
History
- Received: Oct 19, 2005
- Revised: Mar 28, 2006
- Accepted: May 25, 2006
- Published in issue: Nov 1, 2006
Key Words
Authors
Metrics & Citations
Metrics
Article Metrics
View all metricsCitations
Download article citation data for:
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Citing Literature
- Georgina Johnson, Mark Onslow, Brenda Carey, Mark Jones, Elaina Kefalianos, Lidcombe Program telehealth treatment for children 6–12 years of age: A Phase II trial, Journal of Fluency Disorders, 10.1016/j.jfludis.2024.106057, 80, (106057), (2024).
- Georgina Johnson, Mark Onslow, Sarah Horton, Elaina Kefalianos, Reduced stuttering for school-age children: A systematic review, Journal of Fluency Disorders, 10.1016/j.jfludis.2023.106015, 78, (106015), (2023).
- Hope Gerlach-Houck, Christopher D. Constantino, Interrupting Ableism in Stuttering Therapy and Research: Practical Suggestions, Perspectives of the ASHA Special Interest Groups, 10.1044/2021_PERSP-21-00109, 7, 2, (357-374), (2022).
- 15 Pharmacological Considerations for the Treatment of Stuttering, Stuttering and Related Disorders of Fluency, 10.1055/b-0042-189426, (2022).
- Alice K. Hart, Lauren J. Breen, Janet M. Beilby, Evaluation of an integrated fluency and Acceptance and Commitment Therapy intervention for adolescents and adults who stutter: Participant perspectives, Journal of Fluency Disorders, 10.1016/j.jfludis.2021.105852, 69, (105852), (2021).
- Ulrich Natke, Anke Kohmäscher, Ulrich Natke, Anke Kohmäscher, Therapie des Stotterns, Stottern, 10.1007/978-3-662-60942-2_11, (153-206), (2020).
- Soo-Eun Chang, Frank H. Guenther, Involvement of the Cortico-Basal Ganglia-Thalamocortical Loop in Developmental Stuttering, Frontiers in Psychology, 10.3389/fpsyg.2019.03088, 10, (2020).
- Emily O’Dell Garnett, Ho Ming Chow, Ai Leen Choo, Soo-Eun Chang, Stuttering Severity Modulates Effects of Non-invasive Brain Stimulation in Adults Who Stutter, Frontiers in Human Neuroscience, 10.3389/fnhum.2019.00411, 13, (2019).
- Susan M. Bowyer, Jennifer Peacock, MEG Imaged Pathways of Stuttering, Magnetoencephalography, 10.1007/978-3-030-00087-5_38, (1147-1166), (2019).
- K. Neumann, Redeflussstörungen im Kindes- und JugendalterSpeech fluency disorders in childhood and adolescence, HNO, 10.1007/s00106-019-0694-7, 67, 7, (547-560), (2019).
View Options
Sign In Options
ASHA member? If so, log in with your ASHA website credentials for full access.
Member Login